Related Experiment Video
Updated: May 1, 2026
06:24
Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma
Published on: July 6, 2022
4.8K
Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study
Amr M Salaheldin Abdel Hamid1, Wael A Ismail Madkour, Ashraf Moawad
1Obstetrics and Gynecology Department, Ain Shams University, Cairo, Egypt, amoura100@yahoo.com.
Archives of Gynecology and Obstetrics
|April 22, 2014
Summary
Cabergoline significantly reduced endometrioma size more effectively than LHRH agonists. This dopamine agonist offers a more efficient, cost-effective, and easier treatment for endometriosis compared to luteinizing hormone-releasing hormone agonists.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Endometrioma, a gynecological condition, often requires effective medical management.
- Current treatments include hormone therapies with varying efficacy and side effect profiles.
Purpose of the Study:
- To compare the efficacy of Cabergoline, a dopamine agonist, with a luteinizing hormone-releasing hormone (LHRH) agonist (triptorelin acetate) in reducing endometrioma size.
- To evaluate the clinical and economic advantages of Cabergoline over LHRH agonists for endometrioma treatment.
Main Methods:
- A prospective, randomized study involving 140 patients with endometrioma was conducted across two medical centers in the UAE.
- Patients were assigned to receive either Cabergoline (0.5 mg twice weekly for 12 weeks) or LHRH agonist (3.75 mg monthly for 3 months).
- Vaginal ultrasound was used to measure endometrioma size changes before and after treatment by blinded sonography teams.
Main Results:
- A significant reduction ( >25%) in endometrioma size was observed in 64.7% of patients treated with Cabergoline, compared to 21.7% with the LHRH agonist.
- The difference in efficacy between the two treatment groups was statistically significant (p < 0.05).
Conclusions:
- Cabergoline demonstrates superior efficacy in decreasing endometrioma size compared to LHRH agonists.
- Cabergoline offers advantages such as fewer side effects, easier administration, and lower cost, potentially mediated by antiangiogenic effects via VEGFR-2 inactivation.
